Uncategorized

Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs

Published

on

Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version